What's Happening?
The proliferation of weight-loss medications, such as Wegovy, Ozempic, and Zepbound, is significantly impacting the U.S. restaurant industry. Customers are reportedly eating less and more frequently requesting to-go boxes for unfinished meals. Deborah
VanTrece, chef and owner of Twisted Soul Cookhouse & Pours in Atlanta, observed a rapid increase in the use of take-out containers, with patrons often leaving half their portions. She noted that when asked, customers openly attribute this change to their use of GLP-1 injections. This shift has led to a decrease in average check sizes, with VanTrece reporting a drop of over 25% in recent months. Consequently, restaurants are exploring strategies like offering smaller portions and special menus to accommodate these new dining behaviors. Dennis Turcinovic, owner of Tucci, an Italian restaurant in New York, has also started offering smaller versions of some dishes.
Why It's Important?
This trend presents a new challenge for the U.S. restaurant industry, which has already been grappling with rising costs since the COVID-19 pandemic. Average hourly wages for employees and wholesale food prices have increased by over 35% since early 2020, leading to approximately one-third of businesses operating at a loss in the first half of this year, according to a survey by the National Restaurant Association. The shift in consumer eating habits due to weight-loss medications could further strain profitability. Restaurants must innovate to remain viable, balancing the need to cater to customers using GLP-1 drugs with the desire to retain those who are not. Fast-food chains, whose menus often feature calorie-dense items, are particularly vulnerable, as GLP-1 users tend to seek out such foods less frequently. The long-term impact could reshape menus, portion sizes, and even the types of ingredients prioritized by restaurants across the country.
What's Next?
Restaurants are expected to continue experimenting with menu adjustments to cater to the evolving preferences of their customers. This includes offering smaller portion sizes, incorporating more protein-rich and lower-calorie options, and potentially exploring new ingredient combinations. Neil Doherty, head of culinary strategy at Sysco, suggests that restaurants might utilize more affordable protein sources like lentils, eggs, or cottage cheese, which are favored by GLP-1 users. He also proposes combining smaller portions of expensive meats with cheaper ingredients, such as a four-ounce steak with shrimp. While some chains like McDonald's, according to CEO Chris Kempczinski, have not yet seen a direct impact, they are testing new items like chicken strip salads and grilled chicken wraps. Burger King is also testing smaller versions of some items, such as Whopper Bites. Shake Shack has already introduced a 'Good Fit' menu with higher-protein, bun-less options. The challenge for these establishments will be to ensure sufficient demand for these new offerings to justify their inclusion on the menu.
Beyond the Headlines
The widespread adoption of weight-loss medications could trigger a broader cultural shift in American dining habits, moving away from the large portion sizes that have become characteristic of the U.S. food landscape. This could lead to a re-evaluation of what constitutes a 'standard' meal in restaurants and potentially influence food manufacturers to develop more portion-controlled or health-conscious products. The ethical dimension arises as restaurants navigate how to adapt without alienating customers who are not using these medications, as universally reducing portion sizes could be perceived negatively. The long-term implications extend to public health, as a sustained reduction in calorie intake across a significant portion of the population could impact obesity rates and related health issues. This trend also highlights the increasing influence of pharmaceutical advancements on consumer behavior and, consequently, on various industries, including the food service sector.
